Details of the Drug

General Information of Drug (ID: DM5ST9Z)

Drug Name
Zolbetuximab
Synonyms IMAB362
Indication
Disease Entry ICD 11 Status REF
Esophagogastric junction neoplasm 2B71 Phase 3 [1]
Gastric adenocarcinoma 2B72 Phase 3 [1]
Pancreatic cancer 2C10 Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB15118
TTD ID
D4HQ1F
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Claudin-18 (CLDN18) TT6PKBX CLD18_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03504397) A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT03816163) A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
3 FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619.